CH679934A5 - - Google Patents

Download PDF

Info

Publication number: CH679934A5
Authority: CH; Switzerland
Prior art keywords: virus; promoter; gene; vfp; antigen
Prior art date: 1987-08-28

Application number

CH1444/91A

Other languages

German (de)

English (en)

Inventor

Enzo Paoletti

Original Assignee

Health Research Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-08-28

Filing date

1988-08-24

Publication date

1992-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27492413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH679934(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1988-08-24 Application filed by Health Research Inc filed Critical Health Research Inc

1992-05-15 Publication of CH679934A5 publication Critical patent/CH679934A5/de

Links

241000700605 Viruses Species 0.000 claims description 172
108090000623 proteins and genes Proteins 0.000 claims description 127
206010037742 Rabies Diseases 0.000 claims description 79
239000000427 antigen Substances 0.000 claims description 53
108091007433 antigens Proteins 0.000 claims description 52
102000036639 antigens Human genes 0.000 claims description 52
206010046865 Vaccinia virus infection Diseases 0.000 claims description 49
208000007089 vaccinia Diseases 0.000 claims description 49
230000014509 gene expression Effects 0.000 claims description 39
241000700663 Avipoxvirus Species 0.000 claims description 36
241000714165 Feline leukemia virus Species 0.000 claims description 29
101710154606 Hemagglutinin Proteins 0.000 claims description 21
101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 21
101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 21
101710176177 Protein A56 Proteins 0.000 claims description 21
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 20
239000000185 hemagglutinin Substances 0.000 claims description 20
241000700662 Fowlpox virus Species 0.000 claims description 17
241000711450 Infectious bronchitis virus Species 0.000 claims description 17
239000011159 matrix material Substances 0.000 claims description 17
241000714266 Bovine leukemia virus Species 0.000 claims description 16
244000052769 pathogen Species 0.000 claims description 16
241000711404 Avian avulavirus 1 Species 0.000 claims description 11
230000001717 pathogenic effect Effects 0.000 claims description 11
241000700584 Simplexvirus Species 0.000 claims description 10
241000712461 unidentified influenza virus Species 0.000 claims description 9
241000178270 Canarypox virus Species 0.000 claims description 8
108010061100 Nucleoproteins Proteins 0.000 claims description 7
102000011931 Nucleoproteins Human genes 0.000 claims description 6
108020001507 fusion proteins Proteins 0.000 claims description 6
230000003362 replicative effect Effects 0.000 claims description 5
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 3
102000037865 fusion proteins Human genes 0.000 claims description 3
208000002979 Influenza in Birds Diseases 0.000 claims description 2
241000713824 Rous-associated virus Species 0.000 claims description 2
101800001271 Surface protein Proteins 0.000 claims description 2
206010064097 avian influenza Diseases 0.000 claims description 2
102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims 1
239000013612 plasmid Substances 0.000 description 134
239000012634 fragment Substances 0.000 description 103
238000002255 vaccination Methods 0.000 description 75
210000004027 cell Anatomy 0.000 description 63
208000015181 infectious disease Diseases 0.000 description 54
239000013598 vector Substances 0.000 description 44
241000287828 Gallus gallus Species 0.000 description 43
235000013330 chicken meat Nutrition 0.000 description 43
238000012360 testing method Methods 0.000 description 41
238000010276 construction Methods 0.000 description 40
238000003780 insertion Methods 0.000 description 39
230000037431 insertion Effects 0.000 description 39
241000271566 Aves Species 0.000 description 38
108020004414 DNA Proteins 0.000 description 38
102000053602 DNA Human genes 0.000 description 38
229960005486 vaccine Drugs 0.000 description 35
238000000034 method Methods 0.000 description 33
108091034117 Oligonucleotide Proteins 0.000 description 32
241000700618 Vaccinia virus Species 0.000 description 32
108010005774 beta-Galactosidase Proteins 0.000 description 32
244000144977 poultry Species 0.000 description 32
230000006798 recombination Effects 0.000 description 32
201000006082 Chickenpox Diseases 0.000 description 31
206010046980 Varicella Diseases 0.000 description 31
235000013594 poultry meat Nutrition 0.000 description 31
241000283973 Oryctolagus cuniculus Species 0.000 description 30
208000000666 Fowlpox Diseases 0.000 description 29
238000005215 recombination Methods 0.000 description 27
241001465754 Metazoa Species 0.000 description 26
230000028993 immune response Effects 0.000 description 24
210000002966 serum Anatomy 0.000 description 23
102000004169 proteins and genes Human genes 0.000 description 22
108090000288 Glycoproteins Proteins 0.000 description 21
108091026890 Coding region Proteins 0.000 description 20
102000003886 Glycoproteins Human genes 0.000 description 20
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 18
102000005936 beta-Galactosidase Human genes 0.000 description 18
108700004025 env Genes Proteins 0.000 description 18
101150030339 env gene Proteins 0.000 description 18
102000004594 DNA Polymerase I Human genes 0.000 description 17
108010017826 DNA Polymerase I Proteins 0.000 description 17
238000000338 in vitro Methods 0.000 description 17
238000002474 experimental method Methods 0.000 description 16
239000002773 nucleotide Substances 0.000 description 16
125000003729 nucleotide group Chemical group 0.000 description 16
101150082239 G gene Proteins 0.000 description 15
241000700647 Variola virus Species 0.000 description 15
230000003902 lesion Effects 0.000 description 14
241000699670 Mus sp. Species 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
230000036961 partial effect Effects 0.000 description 13
230000029087 digestion Effects 0.000 description 12
238000010790 dilution Methods 0.000 description 12
239000012895 dilution Substances 0.000 description 12
241001135961 Amsacta moorei entomopoxvirus Species 0.000 description 11
230000004044 response Effects 0.000 description 11
238000013519 translation Methods 0.000 description 11
241000283690 Bos taurus Species 0.000 description 10
238000002965 ELISA Methods 0.000 description 10
241000588724 Escherichia coli Species 0.000 description 10
241000124008 Mammalia Species 0.000 description 10
238000003018 immunoassay Methods 0.000 description 10
238000001114 immunoprecipitation Methods 0.000 description 10
230000003612 virological effect Effects 0.000 description 10
108091028043 Nucleic acid sequence Proteins 0.000 description 9
108700026244 Open Reading Frames Proteins 0.000 description 9
241000287219 Serinus canaria Species 0.000 description 9
238000003776 cleavage reaction Methods 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 9
239000006166 lysate Substances 0.000 description 9
229920002477 rna polymer Polymers 0.000 description 9
230000007017 scission Effects 0.000 description 9
238000013518 transcription Methods 0.000 description 9
230000035897 transcription Effects 0.000 description 9
108091081024 Start codon Proteins 0.000 description 8
230000000890 antigenic effect Effects 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000009396 hybridization Methods 0.000 description 8
206010022000 influenza Diseases 0.000 description 8
238000011081 inoculation Methods 0.000 description 8
241000282326 Felis catus Species 0.000 description 7
230000036039 immunity Effects 0.000 description 7
238000007918 intramuscular administration Methods 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
230000010076 replication Effects 0.000 description 7
238000007920 subcutaneous administration Methods 0.000 description 7
241001494479 Pecora Species 0.000 description 6
238000010367 cloning Methods 0.000 description 6
230000001419 dependent effect Effects 0.000 description 6
210000002257 embryonic structure Anatomy 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
230000002458 infectious effect Effects 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
238000010186 staining Methods 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
230000003442 weekly effect Effects 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 5
241000286209 Phasianidae Species 0.000 description 5
241000711798 Rabies lyssavirus Species 0.000 description 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 5
235000015278 beef Nutrition 0.000 description 5
230000034994 death Effects 0.000 description 5
231100000517 death Toxicity 0.000 description 5
235000013601 eggs Nutrition 0.000 description 5
239000000523 sample Substances 0.000 description 5
239000002356 single layer Substances 0.000 description 5
241000894007 species Species 0.000 description 5
241000238631 Hexapoda Species 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 4
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 4
230000008901 benefit Effects 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
239000013592 cell lysate Substances 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
230000001506 immunosuppresive effect Effects 0.000 description 4
210000001161 mammalian embryo Anatomy 0.000 description 4
239000003550 marker Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
238000006386 neutralization reaction Methods 0.000 description 4
229920001184 polypeptide Polymers 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
241000700570 unidentified entomopoxvirus Species 0.000 description 4
101150110188 30 gene Proteins 0.000 description 3
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
230000004543 DNA replication Effects 0.000 description 3
201000004624 Dermatitis Diseases 0.000 description 3
101150039660 HA gene Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
208000010668 atopic eczema Diseases 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
210000003555 cloaca Anatomy 0.000 description 3
230000000120 cytopathologic effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
101150036031 gD gene Proteins 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
230000012447 hatching Effects 0.000 description 3
238000002649 immunization Methods 0.000 description 3
238000010166 immunofluorescence Methods 0.000 description 3
238000011065 in-situ storage Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000013507 mapping Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
210000002729 polyribosome Anatomy 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000010257 thawing Methods 0.000 description 3
210000003437 trachea Anatomy 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
101100333573 Bovine leukemia virus env gene Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
101710121417 Envelope glycoprotein Proteins 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
101100484387 Fowlpox virus FPV127 gene Proteins 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000255777 Lepidoptera Species 0.000 description 2
101150118742 NP gene Proteins 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
241000714233 Rous-associated virus type 1 Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
101150003725 TK gene Proteins 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
235000021186 dishes Nutrition 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
229960000380 propiolactone Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
210000001995 reticulocyte Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000004448 titration Methods 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
-1 5-bromo-4-chloro-3-indolyl- Chemical group 0.000 description 1
235000006576 Althaea officinalis Nutrition 0.000 description 1
241000670670 Amsacta Species 0.000 description 1
IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
241001203868 Autographa californica Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102100021935 C-C motif chemokine 26 Human genes 0.000 description 1
101100148606 Caenorhabditis elegans pst-1 gene Proteins 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
241000254173 Coleoptera Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
241000701832 Enterobacteria phage T3 Species 0.000 description 1
241000700572 Entomopoxvirinae Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
206010069540 Generalised vaccinia Diseases 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
HHSJMSCOLJVTCX-ZDLURKLDSA-N L-Glutaminyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCC(N)=O HHSJMSCOLJVTCX-ZDLURKLDSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
241001415864 Lagopus Species 0.000 description 1
241000721703 Lymantria dispar Species 0.000 description 1
208000012266 Needlestick injury Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000238814 Orthoptera Species 0.000 description 1
241000287127 Passeridae Species 0.000 description 1
108010076039 Polyproteins Proteins 0.000 description 1
208000027954 Poultry disease Diseases 0.000 description 1
206010037888 Rash pustular Diseases 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
241000287231 Serinus Species 0.000 description 1
108010008038 Synthetic Vaccines Proteins 0.000 description 1
108010059722 Viral Fusion Proteins Proteins 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
230000003321 amplification Effects 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
244000309466 calf Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229940028617 conventional vaccine Drugs 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
230000008029 eradication Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000012757 fluorescence staining Methods 0.000 description 1
230000036449 good health Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
210000000087 hemolymph Anatomy 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
108010077284 hepatitis B surface antigen presurface protein 2 Proteins 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
229940031551 inactivated vaccine Drugs 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000004237 neck muscle Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
208000029561 pustule Diseases 0.000 description 1
229940124551 recombinant vaccine Drugs 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000018040 scab formation Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
210000000966 temporal muscle Anatomy 0.000 description 1
230000036962 time dependent Effects 0.000 description 1
230000010474 transient expression Effects 0.000 description 1
239000003656 tris buffered saline Substances 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000017613 viral reproduction Effects 0.000 description 1
230000006490 viral transcription Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

CH1444/91A 1987-08-28 1988-08-24 CH679934A5 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US9071187A	1987-08-28	1987-08-28
US11033587A	1987-10-20	1987-10-20
US18605488A	1988-04-25	1988-04-25
US23439088A	1988-08-23	1988-08-23

Publications (1)

Publication Number	Publication Date
CH679934A5 true CH679934A5 (da)	1992-05-15

Family

ID=27492413

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CH1652/89A CH679933A5 (da)	1987-08-28	1988-08-24
CH1444/91A CH679934A5 (da)	1987-08-28	1988-08-24

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CH1652/89A CH679933A5 (da)	1987-08-28	1988-08-24

Country Status (17)

Country	Link
JP (3)	JP3348156B2 (da)
KR (1)	KR970011149B1 (da)
AR (1)	AR241939A1 (da)
AT (1)	AT408549B (da)
AU (2)	AU2427588A (da)
BE (1)	BE1002134A5 (da)
CH (2)	CH679933A5 (da)
DE (4)	DE10399032I1 (da)
DK (1)	DK175904B1 (da)
FR (1)	FR2621487B1 (da)
GB (1)	GB2217718B (da)
IL (1)	IL87581A0 (da)
IT (1)	IT1229484B (da)
LU (2)	LU90951I2 (da)
NL (4)	NL195051C (da)
NZ (1)	NZ225970A (da)
WO (1)	WO1989003429A1 (da)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5505941A (en) *	1981-12-24	1996-04-09	Health Research, Inc.	Recombinant avipox virus and method to induce an immune response
US5338683A (en) *	1981-12-24	1994-08-16	Health Research Incorporated	Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7045313B1 (en)	1982-11-30	2006-05-16	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
DE10399032I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
US5286639A (en) *	1987-09-16	1994-02-15	Nippon Zeon Co., Ltd.	Recombinant avipoxvirus
DE3813093A1 (de) *	1988-04-19	1989-11-09	Immuno Ag	Rekombinantes plasmid, verfahren zum herstellen eines rekombinanten avipoxvirus, rekombinantes avipoxvirus und dessen verwendung
US5631154A (en) *	1988-06-10	1997-05-20	Therion Biologics, Incorporated	Self assembled, defective, non-self-propagating lentivirus particles
US5310671A (en) *	1988-06-24	1994-05-10	British Technology Group Limited	Fowlpox virus non-essential regions
US5093258A (en) *	1988-08-26	1992-03-03	Therion Biologics Corporation	Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) *	1988-10-21	1990-04-21	Matthew M. Binns	Fowlpox virus promoter
US6248333B1 (en)	1990-04-04	2001-06-19	Health Research Inc.	Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5204243A (en) *	1990-02-14	1993-04-20	Health Research Incorporated	Recombinant poxvirus internal cores
MY109299A (en) *	1990-08-15	1996-12-31	Virogenetics Corp	Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) *	1990-08-15	1996-05-07	Virogenetics Corporation	Flavivirus recombinant poxvirus vaccine
FR2668064B1 (fr)	1990-10-23	1994-12-16	Transgene Sa	Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
US5756102A (en) *	1990-11-20	1998-05-26	Virogenetics Corporation	Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
US5759841A (en) *	1990-11-20	1998-06-02	Virogenetics Corporation	Immunological composition of measles virus utilizing recombinant poxvirus
IE68404B1 (en) *	1990-11-20	1996-06-12	Virogenetics Corp	Measles virus recombinant poxvirus vaccine
US5503834A (en) *	1990-11-20	1996-04-02	Virogenetics Corporation	Measles virus recombinant poxvirus vaccine
US6309647B1 (en)	1999-07-15	2001-10-30	Aventis Pasteur	Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
US5338679A (en) *	1991-01-08	1994-08-16	Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada	Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter
US5766597A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Malaria recombinant poxviruses
US5766598A (en) *	1991-03-07	1998-06-16	Virogenetics Corporation	Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
US5863542A (en) *	1991-03-07	1999-01-26	Virogenetics Corporation	Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
EP0575491B1 (en) *	1991-03-07	2003-08-13	Virogenetics Corporation	Genetically engineered vaccine strain
US5756101A (en) *	1991-07-01	1998-05-26	Pasteur Merieux Serums Et Vaccins	Malaria recombinant poxvirus
AU674491B2 (en) *	1991-03-20	1997-01-02	Virogenetics Corporation	Recombinant poxvirus malaria vaccine
DE69233080T2 (de) *	1991-06-14	2004-04-15	Connaught Technology Corp., Greenville	Rekombinanter hiv-spezifischer impfstoff aus poxviru
CA2110505A1 (en) *	1991-07-26	1993-02-18	Enzo Paoletti	Infectious bursal disease virus recombinant poxvirus vaccine
EP1380651A2 (en) *	1991-08-26	2004-01-14	Baxter Healthcare S.A.	Recombinant fowlpox virus with intact FPV-tk-gene
US5443831A (en) *	1991-10-29	1995-08-22	University Of Delaware	Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus
US6127163A (en) *	1992-01-13	2000-10-03	Syntro Corporation	Recombinant swinepox virus
US6033904A (en) *	1992-01-13	2000-03-07	Syntro Corporation	Recombinant swinepox virus
US6251403B1 (en)	1992-01-13	2001-06-26	Syntro Corporation	Recombinant swinepox virus
EP0623172B1 (en) *	1992-01-13	2004-12-29	Virogenetics Corporation	Marek's disease virus recombinant vaccinia virus vaccine
US6497882B1 (en)	1992-01-13	2002-12-24	Syntro Corporation	Recombinant swinepox virus
US5869312A (en) *	1992-01-13	1999-02-09	Syntro Corporation	Recombinant swinepox virus
US6328975B1 (en)	1992-01-13	2001-12-11	Syntro Corporation	Recombinant swinepox virus
WO1994006921A1 (en) *	1992-09-21	1994-03-31	Viagene, Inc.	Recombinant retroviral vector against felv and/or fiv
AU727278B2 (en) *	1993-02-26	2000-12-07	Syntro Corporation	Recombinant fowlpox viruses and uses thereof II
EP0696204A4 (en) *	1993-02-26	1999-03-31	Syntro Corp	Recombined chickenpox virus and its use
US5925358A (en) *	1993-02-26	1999-07-20	Syntro Corporation	Recombinant fowlpox viruses and uses thereof
US6136318A (en) *	1993-02-26	2000-10-24	Cochran; Mark D.	Recombinant fowlpox viruses and uses thereof
US5496731A (en) *	1993-03-25	1996-03-05	Xu; Hong-Ji	Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy
US5843742A (en) *	1994-12-16	1998-12-01	Avigen Incorporated	Adeno-associated derived vector systems for gene delivery and integration into target cells
EP0753581A1 (en)	1995-07-10	1997-01-15	Immuno Ag	Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
US5858373A (en) *	1995-12-01	1999-01-12	Virogenetics Corporation	Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
EP0954593A1 (en)	1996-07-25	1999-11-10	Therion Biologics Corporation	Recombinant pox virus for immunization against tumor-associated antigens
US6106825A (en) *	1997-05-07	2000-08-22	University Of Florida	Entomopoxvirus-vertebrate gene delivery vector and method
WO1999007869A1 (en) *	1997-08-05	1999-02-18	University Of Florida	Live recombinant vaccine comprising inefficiently or non-replicating virus
US6248582B1 (en) *	1997-10-08	2001-06-19	Imran Khan	Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
JPH11165762A (ja)	1997-12-01	1999-06-22	Lintec Corp	チップ体搬送用カバーテープおよび封止構造体
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
US6221349B1 (en)	1998-10-20	2001-04-24	Avigen, Inc.	Adeno-associated vectors for expression of factor VIII by target cells
US6200560B1 (en)	1998-10-20	2001-03-13	Avigen, Inc.	Adeno-associated virus vectors for expression of factor VIII by target cells
AU2221600A (en)	1998-12-31	2000-07-31	Chiron Corporation	Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en)	1998-12-31	2011-05-03	Novartis Vaccines & Diagnostics, Inc	Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
EP1194449B1 (en)	1999-06-28	2010-09-22	Oklahoma Medical Research Foundation	Inhibitors of memapsin 2 and use thereof
SI1650221T1 (sl)	2000-02-23	2012-09-28	Glaxosmithkline Biolog Sa	Nove spojine
EP1319069B1 (en)	2000-06-28	2008-05-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU2002305914A1 (en)	2001-01-12	2002-10-21	Chiron Corporation	Nucleic acid mucosal immunization
BR0207761A (pt) *	2001-03-08	2006-01-31	Akzo Nobel Nv	Uso de um vìrus leporipox recombinante vivo, vacina, e, vìrus leporipox recombinante vivo
JP4499311B2 (ja) *	2001-04-27	2010-07-07	シャープ株式会社	放送受信端末
CA2446788A1 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002320314A1 (en)	2001-07-05	2003-01-21	Chiron, Corporation	Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1409694A4 (en)	2001-07-05	2006-02-08	Chiron Corp	POLYNUCLEOTIDES ENCODING ANTIGENIC POLYPEPTIDES OF HIV SUBTYPE B AND / OR SUBTYPE C, POLYPEPTIDES AND USES THEREOF
EP1581119B1 (en)	2001-12-17	2013-01-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
SI1589934T1 (sl)	2003-01-06	2016-02-29	Corixa Corporation Corporation Service Company	Določene aminoalkil glukozaminid fosfat spojine in njih uporaba
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1628680B1 (en)	2003-05-15	2012-10-24	Novartis Vaccines and Diagnostics, Inc.	Hiv polynucleotides and polypeptides derived from botswana mj4
US7261882B2 (en)	2003-06-23	2007-08-28	Reagents Of The University Of Colorado	Methods for treating neuropathic pain by administering IL-10 polypeptides
ES2730275T3 (es)	2004-09-22	2019-11-11	Glaxosmithkline Biologicals Sa	Composición inmunógena para uso en vacunación contra estafilococos
WO2007081447A2 (en)	2005-11-22	2007-07-19	Novartis Vaccines And Diagnostics, Inc.	Norovirus and sapovirus antigens
WO2007120368A2 (en)	2006-01-09	2007-10-25	The Regents Of The University Of California	Immunostimulatory combinations for vaccine adjuvants
WO2007106536A2 (en)	2006-03-14	2007-09-20	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
CA2678404C (en)	2007-02-28	2019-03-19	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
WO2009049350A1 (en)	2007-10-15	2009-04-23	The University Of Queensland	Expression system for modulating an immune response
US8691502B2 (en)	2008-10-31	2014-04-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
CA2748788C (en)	2009-01-05	2021-02-09	Epitogenesis Inc.	The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response
WO2010099472A2 (en)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Spanx-b polypeptides and their use
US8961989B2 (en)	2009-11-20	2015-02-24	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
WO2011106705A2 (en)	2010-02-26	2011-09-01	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Dna-protein vaccination protocols
US9795658B2 (en)	2010-04-20	2017-10-24	Admedus Vaccines Pty Ltd	Expression system for modulating an immune response
US9428565B2 (en)	2011-01-31	2016-08-30	The General Hospital Corporation	Treatment and bioluminescent visualization using multimodal TRAIL molecules
WO2012151272A2 (en)	2011-05-02	2012-11-08	Tremrx, Inc.	T-cell vaccination with viral vectors via mechanical epidermal disruption
JP2014527398A (ja)	2011-06-21	2014-10-16	オンコファクターコーポレイション	がんの療法および診断のための組成物および方法
EP2723378A4 (en)	2011-06-24	2015-01-28	Epitogenesis Inc	PHARMACEUTICAL COMPOSITIONS COMPRISING A COMBINATION OF VECTORS, VITAMINS, TANNINS AND FLAVONOIDS SELECTED AS ANTIGEN-SPECIFIC IMMUNOMODULATORS
US20150004144A1 (en)	2011-12-02	2015-01-01	The General Hospital Corporation	Differentiation into brown adipocytes
EP2890720B1 (en)	2012-08-30	2019-07-17	The General Hospital Corporation	Compositions and methods for treating cancer
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
WO2014043518A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
US10640771B2 (en)	2013-04-17	2020-05-05	Genzyme Corporation	Compositions and methods for treating and preventing macular degeneration
EP3848045A1 (en)	2013-05-21	2021-07-14	President and Fellows of Harvard College	Engineered heme-binding compositions and uses thereof
WO2015073707A1 (en)	2013-11-15	2015-05-21	The Board Of Trustees Of The Leland Stanford Junior University	Methods of treating heart failure with agonists of hypocretin receptor 2
KR102234695B1 (ko)	2014-02-06	2021-04-02	젠자임 코포레이션	황반 변성을 치료하고 예방하기 위한 조성물 및 방법
EP3194446B1 (en)	2014-09-18	2022-10-26	Cedars-Sinai Medical Center	Compositions and methods for treating fibrosis
EP3270897A4 (en)	2015-03-20	2018-12-05	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
EP3283529B1 (en)	2015-04-17	2023-06-07	The General Hospital Corporation	Agents, systems and methods for treating cancer
EP4194001B1 (en)	2015-04-22	2026-03-18	Cedars-Sinai Medical Center	Enterically delivered bitter oligopeptides for the treatment of type 2 diabetes and obesity
ES2959642T3 (es)	2015-05-13	2024-02-27	The Us Secretary Of The Department Of Health And Human Services	Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
WO2016196366A1 (en)	2015-05-29	2016-12-08	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Extension of replicative lifespan in diseases of premature aging using p53 isoforms
US10550379B2 (en)	2015-06-29	2020-02-04	The Board Of Trustees Of The Leland Stanford Junior University	Degron fusion constructs and methods for controlling protein production
CN108601951B (zh)	2015-12-09	2022-11-22	金港医疗(澳大利亚)私人有限公司	用于治疗的免疫调节组合物
WO2017222911A1 (en)	2016-06-20	2017-12-28	The Board Of Trustees Of The Leland Stanford Junior University	Circular rnas and their use in immunomodulation
US11285191B2 (en)	2016-07-26	2022-03-29	The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Immunostimulatory compositions and uses therefor
CN111344403B (zh)	2017-09-15	2025-05-06	利兰斯坦福初级大学董事会	遗传工程细胞的多元性产生和条形码编制
US10917454B1 (en)	2019-08-01	2021-02-09	Rohde & Schwarz Gmbh & Co. Kg	System and method for ATC voice quality assurance
US20250011787A1 (en)	2021-10-21	2025-01-09	The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads	Retroelement-generated transcription factor decoys
WO2023077147A2 (en)	2021-11-01	2023-05-04	Pellis Therapeutics, Inc.	T-cell vaccines for patients with reduced humoral immunity
US20250043269A1 (en)	2021-11-03	2025-02-06	The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad	Precise Genome Editing Using Retrons
WO2023141602A2 (en)	2022-01-21	2023-07-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
US20250215458A1 (en)	2022-03-25	2025-07-03	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David	Production of reverse transcribed DNA (RT-DNA) using a retron reverse transcriptase from exogenous RNA
US20250223586A1 (en)	2022-03-25	2025-07-10	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David	Methods of assessing engineered retron activity, and uses thereof
US20250215422A1 (en)	2022-03-25	2025-07-03	The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads	RT-DNA Fidelity and Retron Genome Editing
JP2025525569A (ja)	2022-07-18	2025-08-05	レナゲードセラピューティクスマネージメントインコーポレイテッド	遺伝子編集成分、システム、及び使用方法
US20250243516A1 (en)	2022-08-24	2025-07-31	The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David	Dual Cut Retron Editors for Genomic Insertions and Deletions
AU2023329392A1 (en)	2022-08-25	2025-02-27	Renagade Therapeutics Management Inc.	Engineered retrons and methods of use
WO2024233791A1 (en)	2023-05-11	2024-11-14	Seelos Therapeutics, Inc.	Methods of treating neurodegenerative disorders
WO2025081042A1 (en)	2023-10-12	2025-04-17	Renagade Therapeutics Management Inc.	Nickase-retron template-based precision editing system and methods of use
WO2025155753A2 (en)	2024-01-17	2025-07-24	Renagade Therapeutics Management Inc.	Improved gene editing system, guides, and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK489481A (da) *	1980-11-10	1982-05-11	Searle & Co	Plasmidvektor og frmgangsmaade til fremstilling deraf
US4603112A (en) *	1981-12-24	1986-07-29	Health Research, Incorporated	Modified vaccinia virus
AU570940B2 (en) *	1982-11-30	1988-03-31	United States of America, as represented by the Secretary, U.S. Department of Commerce, The	Process for producing poxvirus recombinants for expression offoreign genes
FR2563434B1 (fr) *	1984-04-25	1986-07-25	Transgene Sa	Vaccin contre la rage et procede pour sa preparation
WO1986000528A1 (en) *	1984-07-05	1986-01-30	Genex Corporation	Cloned gene and method for making and using the same
DD235669A1 (de) *	1985-03-26	1986-05-14	Akad Wissenschaften Ddr	Verfahren zur herstellung eines blv-kodierten huellproteins
US5032520A (en) *	1985-03-29	1991-07-16	National Research Development Corporation	DNA sequences encoding infectious bronchitis virus spike protein
AU6170486A (en) *	1985-08-23	1987-02-26	Advanced Genetics Research Institute	Defective viral vaccines
AU607399B2 (en) *	1985-09-09	1991-03-07	Cetus Corporation	Infectious recombinant virus vaccine for feline leukemia
NZ217645A (en) *	1985-09-25	1991-11-26	Oncogen	Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
AU602875B2 (en) *	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
AU8075787A (en) *	1986-09-22	1988-04-07	Australian National University, The	Recombinant poxviruses
WO1988002022A1 (en) *	1986-09-22	1988-03-24	Commonwealth Scientific And Industrial Research Or	Recombinant poxviruses
EP0261940A3 (en) *	1986-09-23	1989-07-05	Applied Biotechnology, Inc.	Pseudorabies vaccines and dna vectors for recombination with pox viruses
DE3853088T2 (de) *	1987-03-27	1995-10-19	Nippon Zeon Co	Rekombinantes Avipoxvirus.
DE10399032I1 (de) *	1987-08-28	2004-01-29	Health Research Inc	Rekombinante Viren.
GB8724885D0 (en) *	1987-10-23	1987-11-25	Binns M M	Fowlpox virus promotors
FR2632863B2 (fr) *	1987-10-29	1990-08-31	Transgene Sa	Virus du fowlpox recombinant et vaccins derives de ces virus
US5310671A (en) *	1988-06-24	1994-05-10	British Technology Group Limited	Fowlpox virus non-essential regions
DE4090351T1 (de) *	1989-03-08	1997-07-24	Health Research Inc	Rekombinantes Pockenvirus-Wirtsselektionssystem
AU658836B2 (en) *	1990-09-25	1995-05-04	Xenova Research Limited	Viral defective vaccine produced by transcomplementing cell line

1987
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/de active Pending
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/de active Pending
1988
- 1988-08-24 DE DE3890874A patent/DE3890874C5/de not_active Expired - Lifetime
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en not_active Ceased
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 AT AT0900788A patent/AT408549B/de not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 JP JP50771588A patent/JP3348156B2/ja not_active Expired - Lifetime
- 1988-08-24 NL NL8820679A patent/NL195051C/nl not_active IP Right Cessation
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/ko not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/de active Pending
- 1988-08-28 IL IL87581A patent/IL87581A0/xx not_active IP Right Cessation
- 1988-08-29 IT IT8821772A patent/IT1229484B/it active
- 1988-08-29 NZ NZ225970A patent/NZ225970A/xx unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/fr not_active IP Right Cessation
- 1988-08-29 FR FR888811334A patent/FR2621487B1/fr not_active Expired - Lifetime
- 1988-08-29 AR AR88311787A patent/AR241939A1/es active
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/da active Protection Beyond IP Right Term
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/ja active Pending
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/ja not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/fr unknown
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/nl unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/fr unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/nl unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/nl unknown

Also Published As

Publication number	Publication date
FR2621487A1 (fr)	1989-04-14
KR970011149B1 (ko)	1997-07-07
JP2002348255A (ja)	2002-12-04
DE10399032I1 (de)	2004-01-29
GB2217718B (en)	1992-05-20
BE1002134A5 (fr)	1990-07-24
GB2217718A (en)	1989-11-01
NL300138I2 (nl)	2004-03-01
JPH02500879A (ja)	1990-03-29
JP3826055B2 (ja)	2006-09-27
NL300139I1 (nl)	2004-02-02
JP2002186494A (ja)	2002-07-02
AR241939A1 (es)	1993-01-29
AU690210B2 (en)	1998-04-23
LU91039I2 (fr)	2003-11-05
ATA900788A (de)	1995-05-15
DK203689A (da)	1989-06-27
DE3890874C5 (de)	2005-10-20
DE3890874C2 (de)	2003-03-13
NZ225970A (en)	1991-01-29
WO1989003429A1 (en)	1989-04-20
LU90951I2 (fr)	2003-01-15
JP3348156B2 (ja)	2002-11-20
NL300138I1 (nl)	2004-02-02
NL300130I1 (nl)	2003-09-01
NL8820679A (nl)	1989-07-03
DK203689D0 (da)	1989-04-27
IT1229484B (it)	1991-09-03
IT8821772A0 (it)	1988-08-29
IL87581A0 (en)	1989-01-31
AU1628895A (en)	1995-08-17
GB8908921D0 (en)	1989-08-02
AU2427588A (en)	1989-05-02
AT408549B (de)	2001-12-27
NL300130I2 (nl)	2005-11-01
DE10399031I1 (de)	2004-01-29
CH679933A5 (da)	1992-05-15
NL195051C (nl)	2003-07-01
DK175904B1 (da)	2005-06-06
FR2621487B1 (fr)	1991-10-18
KR890701757A (ko)	1989-12-21
DE10299049I1 (de)	2004-07-01

Legal Events

Date	Code	Title	Description
2007-09-28	SPCF	Supplementary protection certificate filed	Free format text: PRODUCT NAME: VIRUS CANARYPOX VCP NR. 97; REGISTRATION NUMBER/DATE: IVI 1588 15.03.2007 Filing date: 20070822
2008-08-31	PL	Patent ceased
2009-02-27	SPCG	Supplementary protection certificate granted	Free format text: PRODUCT NAME: VIRUS CANARYPOX VCP97 (FELV); REGISTRATION NUMBER/DATE: IVI 1588 15.03.2007 Spc suppl protection certif: C679934/01 Filing date: 20070822 Extension date: 20130823
2013-08-30	SPCL	Supplementary protection certificate deletion	Spc suppl protection certif: C679934/01

Publication	Publication Date	Title
AT408549B (de)	2001-12-27	Virushältiger impfstoff, rekombinantes virus und verfahren zum exprimieren eines genproduktes
US5174993A (en)	1992-12-29	Recombinant avipox virus and immunological use thereof
US5505941A (en)	1996-04-09	Recombinant avipox virus and method to induce an immune response
AT400955B (de)	1996-05-28	Rekombinantes pockenvirus-wirtsselektionssystem
DE4090565C2 (de)	2000-03-09	Rekombinantes Herpesvirus-Pockenvirus-Vakzin
DE60314823T3 (de)	2017-11-16	Modifizierte variante des vaccinia ankara virus als impfstoff für neugeborene
DE69532068T2 (de)	2004-08-26	Rekombinanter lebender Vogel-Impfstoff, der ein Truthahn-Herpesvirus Vektor gebraucht
DE69535359T2 (de)	2007-10-11	Rekombinantes herpesvirus aus trufhähnen und seine verwendungen
DE3850019T2 (de)	1994-12-01	Rekombinantes Avipoxvirus.
DE69533305T2 (de)	2005-09-01	Lebende rekombinante Vogelvakzine auf eines Vogelherpesvirus gegründet, gegen Gumborokrankheit
DE69735594T2 (de)	2006-11-23	Rekombinanter schweinepockenvirus
DE4192786B4 (de)	2006-08-24	Masernvirus-Rekombinanter Pockenvirus-Impfstoff
DE69627526T2 (de)	2004-04-01	Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
DE69435081T2 (de)	2008-06-12	Rekombinanter adenovirusvektor für geflügel
DE3752182T2 (de)	1998-08-06	Abgeschwächte herpesviren, herpesviren, die eine für aminosäuresequenzen kodierende fremd-dns enthalten, sowie impfstoffe, die diese enthalten
DE69332480T2 (de)	2003-07-17	Impfstoff-vektoren von rekombinantem katzen-herpesvirus
Smith et al.	1994	Development and trial of a bovine herpesvirus 1‐thymidine kinase deletion virus as a vaccine
WO2007115385A2 (en)	2007-10-18	Transfer plasmidic vector and recombinant canarypox virus
CA2084064A1 (en)	1992-01-03	Recombinant pigeon pox virus vaccine
DK175980B1 (da)	2005-10-24	Recombinante vacciniavira og anvendelsen af samme
AU761321B2 (en)	2003-06-05	Recombinant viruses, vaccines containing them and in vitro cell cultures thereof
CA1341403C (en)	2002-11-26	Recombinant a vipox virus
DK176068B1 (da)	2006-03-06	Rekombinant kanaripoxvirus og anvendelsen af samme
DD297997A5 (de)	1992-01-30	Proteine, vakzine und nukleinsaeuren
AU725985B2 (en)	2000-10-26	Recombinant virus